The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review
Open accessAbstract
BACKGROUND: Pharmaceutical companies spent $57.5 billion on pharmaceutical promotion in the United States in 2004. The industry claims that promotion provides scientific and educational information to physicians. While some evidence indicates that promotion may adversely influence prescribing, physicians hold a wide range of views about pharmaceutical promotion. The objective of this review is to examine the relationship between exposure to information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing. METHODS AND FINDINGS: We searched for studies of physicians with prescribing rights who were exposed to information from pharmaceutical companies (promotional or otherwise). Exposures included pharmaceutical sales representative visits, journal advertisements, attendance at pharmaceutical sponsored meetings, mailed information, prescribing software, and participation in sponsored clinical trials. The outcomes measured were quality, quantity, and cost of physicians' prescribing. We searched Medline (1966 to February 2008), International Pharmaceutical Abstracts (1970 to February 2008), Embase (1997 to February 2008), Current Contents (2001 to 2008), and Central (The Cochrane Library Issue 3, 2007) using the search terms developed with an expert librarian. Additionally, we reviewed reference lists and contacted experts and pharmaceutical companies for information. Randomized and observational studies evaluating information from pharmaceutical companies and measures of physicians' prescribing were independently appraised for methodological quality by two authors. Studies were excluded where insufficient study information precluded appraisal. The full text of 255 articles was retrieved from electronic databases (7,185 studies) and other sources (138 studies). Articles were then excluded because they did not fulfil inclusion criteria (179) or quality appraisal criteria (18), leaving 58 included studies with 87 distinct analyses. Data were extracted independently by two authors and a narrative synthesis performed following the MOOSE guidelines. Of the set of studies examining prescribing quality outcomes, five found associations between exposure to pharmaceutical company information and lower quality prescribing, four did not detect an association, and one found associations with lower and higher quality prescribing. 38 included studies found associations between exposure and higher frequency of prescribing and 13 did not detect an association. Five included studies found evidence for association with higher costs, four found no association, and one found an association with lower costs. The narrative synthesis finding of variable results was supported by a meta-analysis of studies of prescribing frequency that found significant heterogeneity. The observational nature of most included studies is the main limitation of this review. CONCLUSIONS: With rare exceptions, studies of exposure to information provided directly by pharmaceutical companies have found associations with higher prescribing frequency, higher costs, or lower prescribing quality or have not found significant associations. We did not find evidence of net improvements in prescribing, but the available literature does not exclude the possibility that prescribing may sometimes be improved. Still, we recommend that practitioners follow the precautionary principle and thus avoid exposure to information from pharmaceutical companies. Please see later in the article for the Editors' Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
(2014) · Medical Entomology and Zoology · Cited by 17,633
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?
Wazana, A. (2000) · JAMA · doi:10.1001/jama.283.3.373 · Cited by 1,415
Gagnon, M.-A., & Lexchin, J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050001 · Cited by 502
Self-citationChren, M. M. (1994) · JAMA · doi:10.1001/jama.271.9.684 · Cited by 397
The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns
Orlowski, J. P., & Wateska, L. (1992) · Chest · doi:10.1378/chest.102.1.270 · Cited by 384
Steinman, M. A., Shlipak, M. G., & McPhee, S. J. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00660-x · Cited by 383
Response Modeling with Nonrandom Marketing-Mix Variables
Manchanda, P., Rossi, P. E., & Chintagunta, P. K. (2004) · Journal of Marketing Research · doi:10.1509/jmkr.41.4.467.47005 · Cited by 317
Rothman, D. J., McDonald, W. J., Berkowitz, C. D., Chimonas, S. C., DeAngelis, C. D., Hale, R. W., Nissen, S. E., Osborn, J. E., Scully, J. H., Thomson, G. E., et al. (2009) · JAMA · doi:10.1001/jama.2009.407 · Cited by 303
The Accuracy of Drug Information From Pharmaceutical Sales Representatives
Ziegler, M. G. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520400066047 · Cited by 297
Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals
Hurwitz, M. A., & Caves, R. E. (1988) · The Journal of Law and Economics · doi:10.1086/467158 · Cited by 254
Temporal Differences in the Role of Marketing Communication in New Product Categories
Narayanan, S., Manchanda, P., & Chintagunta, P. K. (2005) · Journal of Marketing Research · doi:10.1509/jmkr.2005.42.3.278 · Cited by 254
Blumenthal, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmhpr042734 · Cited by 238
Do Pharmaceutical Sales Respond to Scientific Evidence?
Azoulay, P. (2002) · Journal of Economics & Management Strategy · doi:10.1111/j.1430-9134.2002.00551.x · Cited by 198
Are Physicians “Easy Marks”? Quantifying the Effects of Detailing and Sampling on New Prescriptions
Mizik, N., & Jacobson, R. (2004) · Management Science · doi:10.1287/mnsc.1040.0281 · Cited by 197
Interactions between pharmaceutical representatives and doctors in training: A thematic review
Zipkin, D. A., & Steinman, M. A. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0134.x · Cited by 167
Physicians, pharmaceutical sales representatives, and the cost of prescribing
Caudill, T. S. (1996) · Archives of Family Medicine · doi:10.1001/archfami.5.4.201 · Cited by 166
Persuasion or Information? The Economics of Prescription Drug Advertising
Leffler, K. B. (1981) · The Journal of Law and Economics · doi:10.1086/466973 · Cited by 164
Pharmaceutical representatives in academic medical centers
Lurie, N., Rich, E. C., SIMPSON, D. E., Meyer, J., Schiedermayer, D. L., Goodman, J. L., & McKinney, W. P. (1990) · Journal of General Internal Medicine · doi:10.1007/bf02600542 · Cited by 154
Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
Berndt, E. R., Pindyck, R. S., & Azoulay, P. (2000) · Journal of Industrial Economics · doi:10.1111/1467-6451.00200 · Cited by 150
Physicians and Drug Representatives: Exploring the Dynamics of the Relationship
Chimonas, S. C., Brennan, T. A., & Rothman, D. J. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0041-z · Cited by 145
Watkins, C., Harvey, I., Carthy, P., Moore, L., Robinson, E., & Brawn, R. (2003) · BMJ Quality & Safety · doi:10.1136/qhc.12.1.29 · Cited by 141
The role of commercial sources in the adoption of a new drug
Peay, M. Y., & Peay, E. R. (1988) · Social Science & Medicine · doi:10.1016/0277-9536(88)90149-9 · Cited by 139
Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis
Manchanda, P., & Chintagunta, P. K. (2004) · Marketing Letters · doi:10.1023/b:mark.0000047389.93584.09 · Cited by 139
Manchanda, P., & Honka, E. (2005) · PubMed · Cited by 134
Demand Effects of Recent Changes in Prescription Drug Promotion
Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Epstein, A. M., & Frank, R. G. (2003) · Forum for Health Economics & Policy · doi:10.2202/1558-9544.1044 · Cited by 131
Interactions of doctors with the pharmaceutical industry
Morgan, M., Dana, J. D., Loewenstein, G. F., Zinberg, S., & Schulkin, J. A. (2006) · Journal of Medical Ethics · doi:10.1136/jme.2005.014480 · Cited by 127
Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants
Donohue, J. M., & Berndt, E. R. (2004) · Journal of Public Policy & Marketing · doi:10.1509/jppm.23.2.115.51395 · Cited by 122
Understanding why GPs see pharmaceutical representatives: a qualitative interview study.
Prosser, H., & Walley, T. (2003) · Europe PMC (PubMed Central) · Cited by 114
No Free Lunch: Price Premium for Privacy Seal-Bearing Vendors
Mai, B., Menon, N. M., & Sarkar, S. (2010) · Journal of Management Information Systems · doi:10.2753/mis0742-1222270206 · Cited by 113
The effects of detailing on prescribing decisions under quality uncertainty
Ching, A. T., & Ishihara, M. (2010) · Quantitative Marketing and Economics · doi:10.1007/s11129-010-9082-z · Cited by 107
How Conducting a Clinical Trial Affects Physicians' Guideline Adherence and Drug Preferences
Andersen, M. T., Kragstrup, J., & Søndergaard, J. (2006) · JAMA · doi:10.1001/jama.295.23.2759 · Cited by 90
Soumerai, S. B., Avorn, J., Gortmaker, S. L., et al. (1987) · American Journal of Public Health · doi:10.2105/ajph.77.12.1518 · Cited by 90
Impact of Clinical Trial Results on National Trends in α-Blocker Prescribing, 1996-2002
Stafford, R. S. (2004) · JAMA · doi:10.1001/jama.291.1.54 · Cited by 89
Prescribers and Pharmaceutical Representatives: Why Are We Still Meeting?
Fischer, M. A., Keough, M. E., Baril, J. L., Saccoccio, L., Mazor, K. M., Ladd, E., Worley, A. V., & Gurwitz, J. H. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0989-6 · Cited by 89
The Company We Keep: Why Physicians Should Refuse to See Pharmaceutical Representatives
Brody, H. (2005) · The Annals of Family Medicine · doi:10.1370/afm.259 · Cited by 82
Characteristics and Impact of Drug Detailing for Gabapentin
Steinman, M. A., Harper, G. M., Chren, M., Landefeld, C. S., & Bero, L. A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040134 · Cited by 76
When pharmaceutical manufacturersʼ employees present grand rounds, what do residents remember?
Spingarn, R. W., Berlin, J. A., & Strom, B. L. (1996) · Academic Medicine · doi:10.1097/00001888-199601000-00022 · Cited by 72
Muijrers, P. E. M., Grol, R. P. T. M., Sijbrandij, J., et al. (2005) · Family Practice · doi:10.1093/fampra/cmi074 · Cited by 70
New drug uptake: qualitative comparison of high and low prescribing GPs’ attitudes and approach
Prosser, H., & Walley, T. (2003) · Family Practice · doi:10.1093/fampra/cmg516 · Cited by 69
Rutledge, P., Crookes, D., McKinstry, B., & Maxwell, S. R. J. (2003) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.884 · Cited by 63
Berings, D., Blondeel, L., & Habraken, H. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00196105 · Cited by 52
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Kreyenbuhl, J. A., Marcus, S. C., West, J. C., Wilk, J. E., & Olfson, M. (2007) · Psychiatric Services · doi:10.1176/appi.ps.58.7.983 · Cited by 47
Influence of commercial information on prescription quantity in primary care
Caamaño‐Isorna, F. (2002) · European Journal of Public Health · doi:10.1093/eurpub/12.3.187 · Cited by 44
Determinants for the adoption of angiotensin II receptor blockers by general practitioners
Greving, J. P., Denig, P., van der Veen, W. J., Beltman, F. W., Sturkenboom, M., & Haaijer‐Ruskamp, F. M. (2006) · Social Science & Medicine · doi:10.1016/j.socscimed.2006.07.019 · Cited by 42
Determinants of the range of drugs prescribed in general practice: a cross-sectional analysis
de Bakker, D. H., Coffie, D. S., Heerdink, E. R., et al. (2007) · BMC Health Services Research · doi:10.1186/1472-6963-7-132 · Cited by 42
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Kreyenbuhl, J. A., Marcus, S. C., West, J. C., Wilk, J. E., & Olfson, M. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.7.983 · Cited by 38
The drug industry and medical practice—the case of menopausal hormone therapy in Estonia
Hemminki, E., Karttunen, T., Hovi, S., & Karro, H. (2003) · Social Science & Medicine · doi:10.1016/s0277-9536(03)00150-3 · Cited by 23
Montgomery, B. D., Mansfield, P. R., Spurling, G., & Ward, A. M. (2008) · BMC Public Health · doi:10.1186/1471-2458-8-167 · Cited by 22
Self-citationDolovich, L. R., Levine, M., Tarajos, R., & Duku, E. (1999) · Drug Information Journal · doi:10.1177/009286159903300411 · Cited by 14
Freemantle, N., Johnson, R. E., Dennis, J. A., Kennedy, A. D. M., & Marchment, M. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00126.x · Cited by 13
General practitioners and pharmaceutical sales representatives: quality improvement research
Spurling, G., & Mansfield, P. R. (2007) · BMJ Quality & Safety · doi:10.1136/qshc.2006.020164 · Cited by 12
Self-citationVerdoux, H., Cougnard‐Grégoire, A., Grolleau, S., & Bégaud, B. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.001 · Cited by 10
The effect of advertising in clinical software on general practitioners’ prescribing behaviour
Henderson, J., Miller, G. C., Pan, Y., & Britt, H. C. (2008) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb01497.x · Cited by 9
The Effects of Detailing on Prescribing Decisions under Two-Sided Learning
Ching, A. T., & Ishihara, M. (2007) · Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) · Cited by 7
Cited by
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Diabetes in sub-Saharan Africa: from clinical care to health policy
Atun, R., Davies, J. I., Gale, E. A. M., Bärnighausen, T., Beran, D., Kengne, A. P., Levitt, N. S., Mangugu, F. W., Nyirenda, M. J., Ogle, G. D., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30181-x · Cited by 543
DeJong, C., Aguilar, T., Tseng, C.-W., Lin, G. A., Boscardin, W. J., & Dudley, R. A. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2765 · Cited by 517
Drivers of Irrational Use of Antibiotics in Europe
Machowska, A., & Stålsby Lundborg, C. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16010027 · Cited by 383
Medical Marketing in the United States, 1997-2016
Schwartz, L. M., & Woloshin, S. (2019) · JAMA · doi:10.1001/jama.2018.19320 · Cited by 379
Metadata
- Authors
- Spurling, G. K., Mansfield, P. R., Montgomery, B. D., Lexchin, J., Doust, J., Othman, N., & Vitry, A. I.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-10-19
- Volume
- 7
- Issue
- 10
- Pages
- e1000352
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W1964644957
- Cited by
- 526
- References
- 59
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.